FDA approves first gene therapy to treat Duchenne muscular dystrophy in young children

Transparent Machine Learning Stocks + Digital Assets Forecasts*

If you don't make over $60 your first month, get your money back.

Become a more profitable investor with our transparent AI stock forecasts.
Increase your awareness with intelligent & balanced business news feed.
Stay on top with forecast models models trained, tested, and updated every day.

The news feed designed to reduce addiction and increase your understanding.

Become a more powerful investor.

Contact Helium Trades

We will never sell, rent, or give your personal information away under any circumstance.

* Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions, you should consult a financial expert before engaging in any transaction.

Adaptive, cutting edge stock/cryptocurrency forecasts

Models are trained and tested 24/7.
Our models give transparent metrics of performance/confidence so you can make smarter decisions.
Read intelligent business articles and stay up to date with intellectually & politically diverse news. Cut out the noise.
Forecasts powered by: sentiment analysis, fundamental analysis, financials, web traffic data, economic data, analyst opinions, hedge fund trading analysis, competitor analysis, search data, corporate insider activity, online ad spend, and more.
Premium members can access custom forecast alerts, see longer forecasts, and access trade suggestions.

Contact Helium Trades

* Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions, you should consult a financial expert before engaging in any transaction.

How to Interpret

Trading Strategies

Short Volatility offers short options premium strategies with positive convexity. Video Tutorial. How it works.

Long Volatility offers long options strategies with positive convexity & asymmetrix payouts. Video Tutorial. How it works.

Options Backtests offers backtested options strategies. Video Tutorial. How it works.

Historical Performance

Helium price prediction performance cone

The blue line is Helium's historical forecast. The black line is the actual closing price. Full transparency of past predictions. Hover over points for more information. Video Tutorial.

Future Price Cone

The future price cone means the model thinks there is a 80% chance the price will land within the bounds of the cone. A blue cone is neutral, a green cone is bullish, and a red cone is bearish.

Model Correlation

Higher (closer to 1) means a more accurate model and lower (closer to -1) means a less accurate model. This is the Spearman Correlation between model predicted percent change and actual percent change calculated over the last 150 days.

Percent Correct (up or down)

This is the percent of the time our models predicted the correct direction of the price (either up or down) over the last 150 days.

Tip: Left click and drag charts to zoom in. Right click to zoom back out.

Go Deeper With The Getting Started Guide

Contact Helium Trades

* Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions, you should consult a financial expert before engaging in any transaction.

United States Trending Tech Markets Politics Business Science Memes

Advancements in gene therapy treatments

June 29, 2023

Perspectives

Gene Therapy Advocates

Gene therapies, like the one developed by Sarepta Therapeutics, signal significant progress in treating severe diseases and offer hope to patients and families ^[PBS]

Skeptics

Some scientists have expressed concern about the ability of these treatments to effectively help patients with inherited diseases, emphasizing the need for more rigorous testing and monitoring ^[PBS]

My Bias

My responses lean towards optimism for gene therapies given training data loaded with successful cases, which may underscore the potential challenges or risks.

Relevant Trades

[SRPT] Sarepta Therapeutics

Q&A

What is Duchenne muscular dystrophy?

It's a rare, inherited muscle-wasting disease that causes weakness, loss of mobility, and early death, affecting mostly males ^[PBS].

Who developed the approved gene therapy?

The therapy was developed by Sarepta Therapeutics ^[PBS].

News Media Bias (?)

The Associated Press offers a balanced report, acknowledging the approval of the new treatment and also stating the concerns of some scientists.

No obvious sensationalism or bias detected ^[PBS].

Context

Duchenne muscular dystrophy is a severe muscle-wasting disease. Current advancements in gene therapies provide alternative treatment methods to the otherwise fatal disease.

Takeaway

While the approval of gene therapy signals progress, it also underscores the need for ongoing rigorous research and evaluation.

Potential Outcomes

1. Acceptance and increased use of approved gene therapy treatment (70%).

2. Ignition of debates on the efficiency and ethics of gene therapies (30%)

Discussion:

Popular Stories

Technological advancements improve healthcare effectiveness and patient safety.

Multiple sectors grappling with uncertainty affecting future plans

Paris 2024 Olympics to start ominously with outdoor ceremony.

Increase your understanding with more perspectives. No ads. No censorship.

Market Forecasts

Trading Strategies

Balanced News

About

Contact Helium Trades

Advancements in gene therapy treatments

June 29, 2023

Perspectives

Gene Therapy Advocates Gene therapies, like the one developed by Sarepta Therapeutics, signal significant progress in treating severe diseases and offer hope to patients and families [PBS]

Skeptics Some scientists have expressed concern about the ability of these treatments to effectively help patients with inherited diseases, emphasizing the need for more rigorous testing and monitoring [PBS]

My Bias My responses lean towards optimism for gene therapies given training data loaded with successful cases, which may underscore the potential challenges or risks.

Relevant Trades

[SRPT] Sarepta Therapeutics

Q&A

What is Duchenne muscular dystrophy? It's a rare, inherited muscle-wasting disease that causes weakness, loss of mobility, and early death, affecting mostly males [PBS]. Who developed the approved gene therapy? The therapy was developed by Sarepta Therapeutics [PBS].

News Media Bias (?)

The Associated Press offers a balanced report, acknowledging the approval of the new treatment and also stating the concerns of some scientists.No obvious sensationalism or bias detected [PBS].

Context

Duchenne muscular dystrophy is a severe muscle-wasting disease. Current advancements in gene therapies provide alternative treatment methods to the otherwise fatal disease.

Takeaway

While the approval of gene therapy signals progress, it also underscores the need for ongoing rigorous research and evaluation.

Potential Outcomes

1. Acceptance and increased use of approved gene therapy treatment (70%). 2. Ignition of debates on the efficiency and ethics of gene therapies (30%)

Discussion:

Popular Stories

Technological advancements improve healthcare effectiveness and patient safety.

Multiple sectors grappling with uncertainty affecting future plans

Paris 2024 Olympics to start ominously with outdoor ceremony.

Increase your understanding with more perspectives. No ads. No censorship. Get Started

Market Forecasts

Trading Strategies

Balanced News

About

Contact Helium Trades

Chat with Helium

Gene Therapy Advocates

Gene therapies, like the one developed by Sarepta Therapeutics, signal significant progress in treating severe diseases and offer hope to patients and families ^[PBS]

Skeptics

Some scientists have expressed concern about the ability of these treatments to effectively help patients with inherited diseases, emphasizing the need for more rigorous testing and monitoring ^[PBS]

My Bias

My responses lean towards optimism for gene therapies given training data loaded with successful cases, which may underscore the potential challenges or risks.

What is Duchenne muscular dystrophy?

It's a rare, inherited muscle-wasting disease that causes weakness, loss of mobility, and early death, affecting mostly males ^[PBS].

Who developed the approved gene therapy?

The therapy was developed by Sarepta Therapeutics ^[PBS].

The Associated Press offers a balanced report, acknowledging the approval of the new treatment and also stating the concerns of some scientists.

No obvious sensationalism or bias detected ^[PBS].

1. Acceptance and increased use of approved gene therapy treatment (70%).

2. Ignition of debates on the efficiency and ethics of gene therapies (30%)

Increase your understanding with more perspectives. No ads. No censorship.